CoChat
Sign Up
Cited by 54

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability

Stiles, Mitchell F., Campbell, Leanne R., Graff, Donald W., Jones, Bobbette A., Fant, Reginald V., Henningfield, Jack E.·2017·Psychopharmacology
DOI 10.1007/s00213-017-4665-yPMC PMC5548902
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00213-017-4665-y

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mean ratings for the urge to smoke question “How strong is your current urge to smoke your usual brand cigarette?”
Fig. 1 Mean ratings for the urge to smoke question “How strong is your current urge to smoke your usual brand cigarette?”CC BY · PubMed Central
Fig. 2 Mean plasma nicotine concentration profiles
Fig. 2 Mean plasma nicotine concentration profilesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 56

  1. Abrams DB (2014) Promise and peril of e-cigarettes: can disruptive technology make cigarettes obsolete? JAMA 311(2):135–136 · DOI
  2. Abrams DB, Niaura R (2015) The importance of science-informed policy and what the data really tell us about e-cigarettes. Isr J Health Policy Res 4(22). doi: 10.1186/s13584-015-0021-z · DOI
  3. Barbeau AM, Burda J, Siegel M (2013) Perceived efficacy of e-cigarettes versus nicotine replacement therapy among successful e-cigarette users: a qualitative approach. Addict Sci Clin Pract 8:5. doi: 10.1186/1940-0640-8-5 · DOI
  4. Benowitz NL, Hansson A, Jacob P III (2002) Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension 39:1107–1112 · DOI
  5. Calderon SN, Klein MA (2014) A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States. Neuropharmacology 87:97–103 · DOI
  6. Caponnetto P, Campagna D, Papale G, Russo C, Polosa R (2012) The emerging phenomenon of electronic cigarettes. Expert Rev Respir Med 6:63–74. doi: 10.1586/ers.11.92 · DOI
  7. Carter LP, Stitzer ML, Henningfield JE, O’Connor RJ, Cummings KM, Hatsukami DK (2009) Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol Biomark Prev 18:3241–3262. doi: 10.1158/1055-9965.EPI-09-0948 · DOI · Paper page
  8. Cone EF, Fant RV, Henningfield JE (2012) Nicotine and tobacco. In: Mozayani A, Raymon L (eds) Handbook of drug interactions, 2nd edn. Humana Press, New York, pp 587–624 · DOI
  9. Etter JF, Bullen C (2013) A longitudinal study of electronic cigarette users. Addict Behav 39(2):491–494 · DOI
  10. Evans S, Hoffman A (2014) Electronic cigarettes: abuse liability, topography and subjective effects. Tob Control 23(Suppl 2):ii23–ii29 · DOI
  11. Fagerström KO (2012) Determinants of tobacco use and renaming the FTND to the Fagerström Test for Cigarette Dependence. Nicotine Tob Res 14:75–78 · DOI
  12. Fagerström K, Eissenberg T (2012) Dependence on tobacco and nicotine products: a case for product-specific assessment. Nicotine Tob Res 14(11):1382–1390 · DOI
  13. Fant RV, Pickworth WB, Henningfield JE (1997) The addictive effects of nicotine are related to the speed of delivery. In: Opitz K (ed) Nicotine as a therapeutic agent, immunity and the environment, vol 10. Gustav-Fisher, Stuttgart, pp 53–61
  14. Fant RV, Henningfield JE, Nelson RA, Pickworth WB (1999) Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control 8(4):387–392 · DOI · Paper page
  15. Farsalinos KE, Polosa R (2014) Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf 5(2):67–86. doi: 10.1177/2042098614524430 · DOI
  16. Farsalinos K, Romagna G, Tsiapras D, Kyrzopoulos S, Voudris V (2013) Evaluation of electronic cigarette use (vaping) topography and estimation of liquid consumption: implications for research protocol standards definition and for public health authorities’ regulation. Int J Res Public Health 10:2500–2514. doi: 10.3390/ijerph10062500 · DOI
  17. Farsalinos KE, Spyrou A, Stefopoulos C, Tsimopoulou K, Kourkoveli P, Tsiapras D, Kyrzopoulos S, Poulas K, Voudris V (2015) Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naïve users (smokers). Sci Rep 5:11269. doi: 10.1038/srep11269 · DOI
  18. Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, Rosik-Dulewska C, Havel C, Jacob P, Benowitz N (2014) Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 23(2):133–139. doi: 10.1136/tobaccocontrol-2012-050859 · DOI
  19. Grudzinskas C, Balster RL, Gorodetzky CW, Griffiths RR, Henningfield JE, Johanson CE, Mansbach RS, McCormick CG, Schnoll SH, Strain EC, Wright C (2006) Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend 83(Suppl 1):S77–S82 · DOI
  20. Hajek P, Etter J, Benowitz N, Eissenberg T, McRobbie H (2014) Electronic cigarettes: review of use, content, safety, effects on smokers and potential for harm and benefit. Addiction 109:1801–1810. doi: 10.1111/add.12659 · DOI · Paper page
  21. Hatsukami DK (2013) Ending tobacco-caused mortality and morbidity: the case for performance standards for tobacco products. Tob Control 22(Supple 1):i36–i37. doi: 10.1136/tobaccocontrol-2012-050785 · DOI
  22. Hecht S, Carmella S, Kotandeniya D, Pillsbury M, Chen M, Ransom B, Isaksson V, Thompson E, Murphy S, Hatsukami D (2015) Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res 17:704–709. doi: 10.1093/ntr/ntu218 · DOI
  23. Henningfield JE, Keenan RM (1993) Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 61(5):743–750 · DOI · Paper page
  24. Henningfield JE, Hatsukami DK, Zeller M, Peters E (2011) Conference on abuse liability and appeal of tobacco products: conclusions and recommendations. Drug Alcohol Depend 116:1–7 · DOI
  25. Houstsmuller EJ, Fant RV, Eissenberg TE, Henningfield JE, Stitzer ML (2002) Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav 72:559–568 · DOI
  26. Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A (1984) Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 98:334–341
  27. Johnson MW, Bickel WK, Kirshenbaum AP (2004) Substitutes for tobacco smoking: a behavioral economic analysis of nicotine gum, denicotinized cigarettes, and nicotine-containing cigarettes. Drug Alcohol Depend 74(3):253–264 · DOI
  28. Jones HE (2004) Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect 2(2):4–20 · DOI
  29. Kozlowski LT, Strasser AA, Giovino GA, Erickson PA, Terza JV (2001) Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control 10(3):201–203. doi: 10.1136/tc.10.3.201 · DOI
  30. McColl S, Sellers EM (2006) Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend 83S:S52–S62 · DOI
  31. Murray RP, Bailey WC, Daniels K, Bjornson WM, Kurnow K, Connett JE, Nides MA, Kiley JP (1996) Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Chest 109:438–445 · DOI
  32. Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED (2012) Nicotine treatment of mild cognitive impairment. Neurology 78:91–101. doi: 10.1212/WNL.0b013e31823efcbb · DOI
  33. Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerström K, Letlape K, Milton A, Polosa R, Ramsey J, Sweanor D (2014) Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res 20:218–225. doi: 10.1159/000360220 · DOI
  34. O’Connor RJ (2012) Non-cigarette tobacco products: what have we learnt and where are we headed? Tob Control 21(2):181–190. doi: 10.1136/tobaccocontrol-2011-050281 · DOI
  35. Rass O, Pacek LR, Johnson POS, Johnson MW (2015) Characterizing use patterns and percentions of relative harm in dual users of electronic and tobacco cigarettes. Exp Clin Psychopharmacol 23(6):494–503 · DOI
  36. Reissig CJ, Harrison JA, Carter LP, Griffiths RR (2015) Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology 232(5):871–883 · DOI
  37. Royal College of Physicians of London (2000) Nicotine addiction in Britain. Lavenham Press, Ltd., Sudbury, pp 92–100
  38. Schuh KJ, Schuh LM, Henningfield JE, Stitzer ML (1997) Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology 130(4):352–361 · DOI
  39. Schuster CR, Henningfield J (2003) Conference on abuse liability assessment of CNS drugs. Drug Alcohol Depend 70(Suppl 3):S1–S4 · DOI
  40. Shiffman S, Elash CA, Paton SM, Gwaltney CJ, Paty JA, Clark DB, Liu KS, Di Marino ME (2000) Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. Addiction 95(8):1185–1195 · DOI
  41. Shiffman S, Cone EJ, Buchhalter AR, Henningfield JE, Rohay JM, Gitchell JG, Pinney JM, Chau T (2009) Rapid absorption of nicotine from new nicotine gum formulations. Pharmacol Biochem Behav 91:380–384. doi: 10.1016/j.pbb.2008.08.012 · DOI
  42. Shihadeh A, Eissenberg T (2015) Electronic cigarette effectiveness and abuse liability: predicting and regulating nicotine flux. Nicotine Tob Res 17(2):158–162 · DOI
  43. Spindle T, Breland A, Karaoghlanian N, Shihadeh A, Eissenberg T (2015) Preliminary results of an examination of electronic cigarette user puff topography: the effect of a mouthpiece-based topography measurement on plasma nicotine and subjective effects. Nicotine Tob Res 17:142–149. doi: 10.1093/ntr/ntu186 · DOI
  44. Stitzer ML, de Wit H (1998) Abuse liability of nicotine. In: Benowitz NL (ed) Nicotine safety and toxicity. Oxford University Press, New York, pp 119–131 · DOI
  45. The Expert Panel, Henningfield JE, Johanson CE, Sellers EM (2003) Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. Drug Alcohol Depend 70(Suppl):S107–S114. doi: 10.1016/S0376-8716(03)00103-0 · DOI
  46. U. S. Department of Health and Human Services (2010) How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. U. S. Government Printing Office, Washington, D. C
  47. U. S. Department of Health and Human Services (2014) The health consequences of smoking - 50 years of progress: a report of the Surgeon General. Department of Health and Human Services, Public Health Service, Office of the Surgeon General. U. S. Government Printing Office, Washington, D. C
  48. Vansickel AR, Eissenberg T (2012a) Electronic cigarettes: effective nicotine delivery after acute administration. Nicotine Tob Res 15:267–270. doi: 10.1093/ntr/ntr316 · DOI
  49. Vansickel AR, Cobb CO, Weaver MF, Eissenberg T (2010) A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomark Prev 19:1945–1953. doi: 10.1158/1055-9965.EPI-10-0288 · DOI
  50. Vansickel AR, Weaver MF, Eissenberg T (2012b) Clinical laboratory assessment of the abuse liability of an electronic cigarette. Addiction 107:1493–1500. doi: 10.1111/j.1360-0043.2012.03791.x · DOI
  51. Waldum HL, Nilsen OG, Nilsen T, Rørvik H, Syversen V, Sanvik AK, Haugen OA, Torp SH, Brenna E (1996) Long-term effects of inhaled nicotine. Life Sci 58:1339–1346 · DOI
  52. Warner KE, Slade J, Sweanor DT (1997) The emerging market for long-term nicotine maintenance. JAMA 278(13):1087–1092 · DOI
  53. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A (2000) A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray, and inhaler. Psychopharmacology 149:198–202 · DOI
  54. Yan X, D’Ruiz C (2015) Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. Regul Toxicol Pharmacol 71:24–34. doi: 10.1016/j.yrtph.2014.11.004 · DOI
  55. Zeller M (2013) Reflections on the ‘endgame’ for tobacco control. Tob Control 22:i40–i41. doi: 10.1136/tobaccocontrol-2012-050789 · DOI
  56. Zeller MR, Hatsukami D (2009) Strategic Dialogue on Tobacco Harm Reduction Group. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control 18:324–332. doi: 10.1136/tc.2008.027318 · DOI

Cited by

Sorted by citations

See all 54

Metadata

Authors
Stiles, M. F., Campbell, L. R., Graff, D. W., Jones, B. A., Fant, R. V., & Henningfield, J. E.
Venue
Psychopharmacology
Publisher
Springer Science and Business Media LLC
Published
2017-06-20
Volume
234
Issue
17
Pages
2643-2655
ISSN
  • 0033-3158
  • 1432-2072
DOI
10.1007/s00213-017-4665-y
PMC
PMC5548902
Cited by
54
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0 (unspecified)
Funders
RJ Reynolds Vapor Company through its affiliate RJ Reynolds Tobacco Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability. https://app.cochat.ai/papers/10.1007/s00213-017-4665-y
The paper
Stiles, M. F., Campbell, L. R., Graff, D. W., Jones, B. A., Fant, R. V., & Henningfield, J. E. (2017). Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability. Psychopharmacology. https://doi.org/10.1007/s00213-017-4665-y